FDA Approves Repeat Administration of iDose TR Intracameral Implant for Glaucoma Treatment

The US Food and Drug Administration has approved a labeling supplement permitting repeat administration of iDose TR (搜索)搜索该药品 (travoprost查看药品详情 intracameral implant) for the reduction of intraocular pressure in patients with open-angle glaucoma (搜索)搜索该疾病 or ocular hypertension (搜索)搜索该疾病. Announced on January 28, 2026, this update modifies prior labeling that limited use to a single administration and addresses a practical limitation of long-duration intracameral therapy.

Clinical Significance and Unmet Need

Glaucoma remains a leading cause of irreversible blindness worldwide, with intraocular pressure reduction as the only proven modifiable risk factor. While prostaglandin analog eye drops are widely recommended as first-line therapy due to their efficacy and once-daily dosing, real-world adherence to topical therapy is suboptimal. Studies estimate that 30% to 50% of patients do not use drops as prescribed, with factors including ocular surface disease, difficulty with instillation, cost, and treatment fatigue contributing to poor adherence.

Procedural drug delivery approaches, including intracameral implants, aim to bypass adherence barriers while providing sustained intraocular pressure control. Until recently, these strategies were constrained by questions surrounding repeatability, reversibility, and long-term corneal safety—particularly endothelial cell loss, a known risk with intraocular devices and procedures.

Device Technology and Mechanism

iDose TR (搜索)搜索该药品 is a titanium-based intracameral implant that continuously elutes a proprietary, preservative-free formulation of travoprost查看药品详情 into the anterior chamber via membrane-controlled diffusion. The device contains 75 μg of travoprost and is implanted through the trabecular meshwork into the scleral tissue. The FDA originally approved iDose TR in 2023 for a single administration to reduce intraocular pressure in adults with open-angle glaucoma (搜索)搜索该疾病 or ocular hypertension (搜索)搜索该疾病.

Travoprost查看药品详情 is a prostaglandin F2α (搜索)搜索该靶点 analog that lowers intraocular pressure by increasing uveoscleral outflow. iDose TR (搜索)搜索该药品 represents an extension of this mechanism via continuous intraocular delivery rather than episodic topical dosing, allowing for 24/7 release of medication.

Updated Labeling and Clinical Evidence

The newly approved labeling supplement allows re-administration in patients who maintain a "healthy cornea," defined by corneal endothelial cell density parameters outlined in the updated prescribing information. According to the new label, repeat administration requires removal of the original implant and intracameral placement of a new device under standard aseptic conditions.

The approval was supported by pooled corneal safety data from phase 3 pivotal trials and a phase 2b study, which followed patients for up to 3 years after implantation. In these studies, no clinically significant corneal endothelial cell loss was observed over time. The manufacturer also cited results from an "exchange" study evaluating removal of the original implant and placement of a second iDose TR (搜索)搜索该药品, with 12 months of follow-up demonstrating acceptable safety and tolerability.

Safety Profile and Efficacy Data

Across controlled studies of single administration, commonly reported ocular adverse reactions (2%–6%) included increased intraocular pressure, iritis, dry eye, ocular hyperemia, eye pain, visual field defects, and reduced visual acuity. Consistent with other prostaglandin analogs, increased iris pigmentation has been reported and may be permanent.

In the phase 3 GC-010 and GC-012 trials, iDose TR (搜索)搜索该药品 demonstrated sustained intraocular pressure reduction comparable to topical timolol查看药品详情 through 12 months, with durability extending beyond 24 months in extension analyses. In 36-month follow-up data, approximately 70% of iDose TR patients remained well-controlled on the same or fewer intraocular pressure-lowering topical medications at 36 months after a single administration, versus 58% of timolol control subjects.

Clinical Implications and Future Outlook

"[This] should help expand access for patients who may benefit from repeat treatment and provide physicians with greater flexibility in managing their glaucoma patients over time," said Thomas Burns, Glaukos (搜索)搜索该公司 chairman and CEO. "This approval further validates iDose TR (搜索)搜索该药品's established and proven safety profile and reinforces its leading position in addressing the strong and growing demand within the ophthalmic community for safe, effective, and sustained procedural pharmaceutical alternatives to traditional topical medications."

For clinicians managing chronic glaucoma, the labeling change addresses how to maintain sustained prostaglandin exposure beyond the life of an initial implant while preserving corneal safety. Repeat dosing may expand the role of procedural pharmacotherapy for patients who struggle with adherence or tolerability of topical medications.

However, the labeling update does not establish superiority over topical therapy or other sustained-release options, nor does it define optimal timing for re-administration. Evidence supporting repeat administration is primarily safety-focused, with limited published data on long-term efficacy after reimplantation. Real-world outcomes, cost-effectiveness, and patient-reported measures will be critical to defining the role of repeat intracameral therapy in routine practice.

According to Joel Schuman, MD, of Wills Eye Hospital in Philadelphia, Pennsylvania, sustained release and controlled drug delivery approaches are most likely going to grow in number. "The FDA has already approved [these implants], and I think that we're going to see more devices like that," Schuman noted, while acknowledging that adoption will be influenced by factors such as cost, safety signals, patient acceptance, and workflow considerations.